Work Here?
About HeartFlow
Industries
Healthcare
Company Size
501-1,000
Company Stage
Debt Financing
Total Funding
$1B
Headquarters
Redwood City, California
Founded
2010
Overview
HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main clients are healthcare providers seeking safer and more efficient diagnostic methods. The company's product offerings include the HeartFlow Analysis, which consists of various analyses like FFRCT, RoadMap, Plaque, and HeartFlow Planner, all of which have received FDA clearance and are available in the U.S., U.K., Japan, and Canada. HeartFlow differentiates itself from competitors by focusing on non-invasive solutions that enhance treatment planning. The company's goal is to improve cardiovascular care by providing tools that make diagnosis and treatment safer and easier.
Simplify's Take
What believers are saying
- HeartFlow's technology aligns with the growing trend of AI adoption in healthcare.
- The global non-invasive cardiac imaging market is projected to grow significantly, benefiting HeartFlow.
- Updated AHA guidelines emphasize non-invasive testing, increasing demand for HeartFlow's FFRCT Analysis.
What critics are saying
- Emerging AI-driven cardiovascular tools could threaten HeartFlow's market share.
- HeartFlow's reliance on continuous funding rounds indicates potential financial instability.
- New regulatory requirements for AI in healthcare could necessitate costly adjustments for HeartFlow.
What makes HeartFlow unique
- HeartFlow offers a unique AI-driven non-invasive cardiac test for coronary artery visualization.
- The company's technology integrates over two decades of scientific evidence with AI advancements.
- HeartFlow is the only provider offering both anatomical and physiological coronary artery visualization.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1040.6M
Above
Industry Average
Funded Over
10 Rounds
Benefits
Remote Work Options
Stock Options
401(k) Company Match
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↓ -2%HeartFlow has filed a notice for an exempt offering of securities to raise $50 million in new debt financing. This filing with the U.S. Securities and Exchange Commission is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, specifically under Rule 504 or 506 of Regulation D or Section 4(a)(5). The notice must be filed within 15 days after the first sale of securities in the offering.
Heartflow, Inc. announced a $98 million convertible notes financing led by its parent company, Heartflow Holding, Inc. New and existing investors, including Fidelity Management, Janus Henderson, and Bain Capital, participated. The funds will support R&D to advance Heartflow's AI-driven coronary care platform. Heartflow's technology, recognized for innovation, aims to improve CAD diagnosis and management. The platform has been used for over 400,000 patients globally.
Heartflow was recently named one of Fast Company's Most Innovative Companies in Medical Devices for 2025 and won the Innovation in Cardiac Imaging award at the Global Cardiovascular Awards 2025.
HeartFlow and Boone Heart Institute Launch GAMEFILM Registry to Study Heart Health in Retired NFL Players. by Fred Pennic 01/22/2025 Leave a Comment. What You Should Know: – HeartFlow, a global leader in AI-driven heart care solutions, and Boone Heart Institute, a renowned cardiovascular care provider in Denver, today announced the launch of the GAMEFILM Registry. – GAMEFILM Registry will utilize advanced imaging and AI technology to assess and better understand coronary artery disease (CAD) risk in retired National Football League (NFL) players.Understanding the Unique Cardiovascular Risks of Retired NFL PlayersCardiovascular disease remains the leading cause of death globally. Despite advancements in diagnostics, many heart attacks and strokes occur in individuals without prior symptoms. Early identification of high-risk individuals is critical for effective prevention and treatment. Retired NFL players often face unique cardiovascular health challenges due to the intense physical demands of their careers
HeartFlow announces new Category I CPT code from the American Medical Association for ai-enabled Plaque Analysis to assess risk for coronary artery disease.
HeartFlow is Hiring for 43 Jobs on Simplify!
Find jobs on Simplify and start your career today
About HeartFlow
Industries
Healthcare
Company Size
501-1,000
Company Stage
Debt Financing
Total Funding
$1B
Headquarters
Redwood City, California
Founded
2010
HeartFlow is Hiring for 43 Jobs on Simplify!
Find jobs on Simplify and start your career today